Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancerReza Ghasemi(Washington University in St. Louis), Stefano Iacobelli(CTI BioPharma (Italy))OncogenesisAugust 18, 201410.1038/oncsis.2014.31Cited by 19SaveCiteExport RISWatch citationsRelated PapersGalectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?|Trends in Immunology|2002|530Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells|Leukemia|2020|30Whole-genome sequencing reveals individual and cohort level insights into chromosome 9p syndromes|Genome Medicine|2025|5